Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). EMANATE trial topline results disclosed: binary readout event; clinical outcome directly drives near-term valuation and pipeline de-risking.
RHYTHM PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- EMANATE trial topline results disclosed: binary readout event; clinical outcome directly drives near-term valuation and pipeline de-risking
- Results delivered via press release and investor presentation: full data accessible in accompanying exhibits for detailed efficacy/safety metrics
- EMANATE trial outcome determines commercial/regulatory pathway for underlying asset: material catalyst for RYTM shareholders
Item 8.01 · Other Events
- EMANATE trial failed all four primary endpoints; none of the four genetic substudies achieved statistical significance (all p-values >0.05)
- Post hoc LOCF analyses showed significant BMI reductions in POMC/PCSK1 Hets (–5.5%, p=0.0010) and SRC1 (–6.2%, p<0.0001): but post hoc data is hypothesis-generating, not regulatory-grade evidence
- Completers-only analysis showed stronger signals (–9.7% POMC/PCSK1, –8.0% SRC1), but small subgroups (n=41, n=29) limit interpretability
- LEPR Hets and SH2B1 substudies showed negligible effect (–3.6%, p=0.94; –1.7%, p=0.43), effectively ruling out setmelanotide for these genotypes
- Rhythm pivoting to next-gen MC4R agonists bivamelagon and RM-718 for SRC1/POMC paths, signaling EMANATE data insufficient to support a regulatory submission for setmelanotide in these indications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RHYTHM PHARMACEUTICALS, INC. 8-K filings
Get the next RYTM 8-K as it lands
Follow RYTM for push alerts, or ask the research agent what this filing means.